Pre-made Epratuzumab benchmark antibody ( Whole mAb, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-190

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-190 Category Tag

Product Details

Pre-Made Epratuzumab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).

Products Name (INN Index)

Pre-Made Epratuzumab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody

INN Name

Epratuzumab

Target

CD22

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

5vkk:AB:HL/5vl3:EF:AB:HL:CD

95-98% SI Structure

None

Year Proposed

1999

Companies

Charite – Universitatsmedizin Berlin,Children's Oncology Group,Immunomedics,National Cancer Institute (USA),UCB

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Precursor cell lymphoblastic leukaemia-lymphoma,Systemic lupus erythematosus,Non-Hodgkin's lymphoma,Cachexia

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CD22

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide